BOLT Bolt Biotherapeutics Inc

Price (delayed)

$0.7301

Market cap

$27.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$41.38M

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach ...

Highlights
The revenue has soared by 68% YoY and by 44% QoQ
Bolt Biotherapeutics's gross profit has soared by 68% YoY and by 44% from the previous quarter
The quick ratio has contracted by 29% YoY but it has grown by 10% from the previous quarter
The equity is down by 34% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of BOLT
Market
Shares outstanding
38.13M
Market cap
$27.84M
Enterprise value
$41.38M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.27
Price to sales (P/S)
2.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.65
Earnings
Revenue
$11.32M
EBIT
-$63.03M
EBITDA
-$58.18M
Free cash flow
-$63.08M
Per share
EPS
-$1.66
Free cash flow per share
-$1.66
Book value per share
$2.73
Revenue per share
$0.3
TBVPS
$3.75
Balance sheet
Total assets
$142.89M
Total liabilities
$38.73M
Debt
$19.57M
Equity
$104.16M
Working capital
$78.33M
Liquidity
Debt to equity
0.19
Current ratio
5.68
Quick ratio
5.57
Net debt/EBITDA
-0.23
Margins
EBITDA margin
-513.7%
Gross margin
100%
Net margin
-556.6%
Operating margin
-661.2%
Efficiency
Return on assets
-37.7%
Return on equity
-51.7%
Return on invested capital
-39.8%
Return on capital employed
-50%
Return on sales
-556.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BOLT stock price

How has the Bolt Biotherapeutics stock price performed over time
Intraday
-2.65%
1 week
0.01%
1 month
-3.93%
1 year
-46.32%
YTD
-34.81%
QTD
-2.65%

Financial performance

How have Bolt Biotherapeutics's revenue and profit performed over time
Revenue
$11.32M
Gross profit
$11.32M
Operating income
-$74.87M
Net income
-$63.03M
Gross margin
100%
Net margin
-556.6%
The revenue has soared by 68% YoY and by 44% QoQ
Bolt Biotherapeutics's gross profit has soared by 68% YoY and by 44% from the previous quarter
The net margin has soared by 54% YoY and by 37% from the previous quarter
Bolt Biotherapeutics's operating margin has increased by 47% YoY and by 32% from the previous quarter

Growth

What is Bolt Biotherapeutics's growth rate over time

Valuation

What is Bolt Biotherapeutics stock price valuation
P/E
N/A
P/B
0.27
P/S
2.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.65
The EPS has grown by 24% YoY and by 9% from the previous quarter
The equity is down by 34% YoY and by 8% from the previous quarter
BOLT's P/B is 33% below its last 4 quarters average of 0.4
The revenue has soared by 68% YoY and by 44% QoQ
The stock's P/S is 56% less than its last 4 quarters average of 5.7

Efficiency

How efficient is Bolt Biotherapeutics business performance
The ROS has soared by 54% YoY and by 37% from the previous quarter
The ROE fell by 15% YoY
Bolt Biotherapeutics's ROA has decreased by 9% YoY
Bolt Biotherapeutics's ROIC has decreased by 8% YoY

Dividends

What is BOLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BOLT.

Financial health

How did Bolt Biotherapeutics financials performed over time
The total assets has declined by 31% year-on-year and by 11% since the previous quarter
The company's current ratio fell by 30% YoY but it rose by 10% QoQ
The debt is 81% less than the equity
BOLT's debt to equity is up by 36% YoY and by 6% from the previous quarter
The equity is down by 34% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.